Search Results
Jun 18, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at
More news about: Pomerantz LLP
Jun 18, 2026, 06:45 ET TORL BioTherapeutics Presents Preliminary Safety and Efficacy Data of Ixotatug Vedotin (TORL-1-23) in Combination with Bevacizumab in Recurrent Ovarian Cancer at ESMO Gynaecological Cancers Congress 2026
1).Presentation DetailsTitle: Preliminary safety and efficacy of ixotatug vedotin (TORL-1-23), a Claudin 6-targeted ADC, in combination with bevacizumab in recurrent ovarian cancerLead Author: Jung-Yun Lee, M.D., Ph.D., Department of Obstetrics and Gynecology,
More news about: TORL Biotherapeutics LLC
Jun 17, 2026, 09:00 ET 10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer
Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platformsPLEASANTON, Calif., June 17, 2026 /PRNewswire/
More news about: 10x Genomics, Inc.
Jun 17, 2026, 08:01 ET Nectin Therapeutics Reports Encouraging Phase 1 Results for NTX1088 in Combination with Keytruda® (pembrolizumab) at ASCO 2026
/PRNewswire/ -- Nectin Therapeutics, a clinical-stage oncology company developing first-in-class immuno-oncology and antibody-drug conjugate (ADC) therapies, today announced the presentation of Phase 1a/1b clinical data of NTX1088 in combination with pembrolizumab (Keytruda®), Merck's
More news about: Nectin Therapeutics, LTD.
Jun 17, 2026, 01:39 ET Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026
comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.Backed
More news about: Akeso, Inc.
Jun 15, 2026, 13:11 ET Lonza Issues Exclusive, Target-Specific License to Antharis Therapeutics to Advance Next-Generation Dual Payload ADCs for Gastrointestinal Cancers
Antharis to advance proprietary dual-payload antibody-drug conjugate (ADC) programs using Lonza's site-specific ADC technologiesReinforces Antharis' and Lonza's position at the forefront of dual-payload ADC development amid growing industry adoption of multi-warhead strategies
More news about: Antharis Therapeutics
Jun 15, 2026, 02:52 ET Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy
advancement of IO2.0 therapies. Regarding its ADC pipeline, Akeso's development of AK146D1 (a Trop2/Nectin4 bispecific ADC) and AK138D1, among other innovations, aims to resolve the toxicity-related limitations of current ADCs and propel the field into the "ADC2.0" era.About AK138D1Injectable
More news about: Akeso, Inc.
Jun 11, 2026, 21:57 ET Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio
established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
More news about: Akeso, Inc.
Jun 11, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at
More news about: Pomerantz LLP
Jun 11, 2026, 03:00 ET Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
Inc.Formosa Pharmaceuticals, Inc. (6838.TW) is a clinical stage biotechnology company featuring its "Double A" strategy, covering Antibody-drug conjugates (ADC) and its proprietary APNT® nanoparticle formulation technology. APNT®, through which APP13007 was developed, improves the dissolution
More news about: Formosa Pharmaceuticals Inc.,
Jun 10, 2026, 20:59 ET GlycoNex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar SPD8
conjugates (ADCs) and biosimilars. Leveraging its expertise in glyco-science, antibody engineering, and biologics development, GlycoNex is advancing its lead ADC program, GNX1021, which has received PMDA approval to initiate a Phase 1 clinical trial in Japan. The company is also developing SPD8, a denosumab biosimilar
More news about: GlycoNex, Inc.
Jun 10, 2026, 05:00 ET Alteogen Showcases ALT-B4's Potential to Transform ADC Development at World ADC Summit 2026
shift in optimizing the PK and safety profile of ADC therapies. We believe these study results further validate the potential of ALT-B4 as a platform to enhance the competitiveness of ADC therapies, and we anticipate that this will support the expansion of ADC partnerships going forward."— Tae-Yon
More news about: Alteogen Inc.
Jun 10, 2026, 03:00 ET NOVOSENSE Highlights Latest IC Advancements Across Automotive, White Goods, Industrial Control, and AI Data Center Power at PCIM Europe 2026
NSI6911F: An ASIL D isolated gate driver designed for SiC and IGBT power stages, featuring high CMTI, 19 A peak drive capability, a 12-bit isolated ADC, and diagnostic and protection functions.NSI1306:
More news about: NOVOSENSE Microelectronics
Jun 09, 2026, 21:00 ET Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs
More news about: Antengene Corporation Limited
Jun 09, 2026, 08:14 ET Kelun-Biotech Partner Windward Bio Announces First Patients Dosed in Phase 2 SIRIUS COPD Study of SKB378/WIN378
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
Jun 09, 2026, 05:30 ET Securing Agentic AI Pushes Network Security Market Up 14 Percent, According to Dell'Oro Group
controls across users, devices, SaaS applications, private applications, and emerging AI usage patterns.Application Delivery Controllers (ADC): Application delivery modernization continued to matter because agentic and AI-adjacent workflows increase the need for resilient application performance,
More news about: Dell'Oro Group
Jun 08, 2026, 19:00 ET China NMPA Grants IND Clearance to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for the Treatment of Late-Stage Solid Tumors, Including Prostate Cancer
ADRX-0405ADRX-0405 is a clinical-stage ADC targeting STEAP1. The ADC is composed of a humanized IgG1 antibody coupled with a novel topoisomerase inhibitor linker-payload through Adcentrx's innovative i-Conjugation technology platform, a core element of its ADC design. The platform utilizes a cleavable
More news about: Adcentrx Therapeutics
Jun 08, 2026, 14:31 ET The Inner Circle acknowledges Forest Young as a Pinnacle Professional Member Inner Circle of Excellence
sequence of consequential commissions. At Interbrand, he led the design of Paper Prison for the Mandela 95 Initiative, honored with a Cannes Lion, an ADC Black Cube, a One Show Gold Pencil, and an AIGA Case. He was recruited by Allison Johnson, Apple's former Global Marketing Officer, to help build the
More news about: The Inner Circle
Jun 08, 2026, 05:45 ET Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
noninferior to standard TCHP, offering a new treatment option for patients who cannot tolerate severe hematologic toxicity.Gastrointestinal Cancers: ADC and Immunotherapy Combination Treatments Show PromiseIn the field of colorectal cancer, the HORIZON-CRC01 study led by Professor Jin Li of
More news about: Hengrui Pharma
Jun 07, 2026, 20:00 ET Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs
More news about: Antengene Corporation Limited
Jun 04, 2026, 22:45 ET WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
Singapore's position as a leading biopharmaceutical hub. On this site, WuXi Biologics' subsidiary WuXi XDC achieved mechanical completion of its Singapore ADC production site in 2025.Spanning approximately 30,000 square meters, the modular DP facility will feature advanced manufacturing lines, centralized
More news about: WuXi Biologics
Jun 04, 2026, 08:30 ET Stronger Together, Shaping the Future | WuXi XDC and BioDlink Successfully Concluded 2026 Open Day
following the strategic integration.The event brought together biotech customers, industry leaders and innovators to explore how an integrated ADC/XDC CRDMO platform can accelerate the development and commercialization of next-generation bioconjugate therapies.SUZHOU,
More news about: BioDlink Biopharm Co., Ltd.
Jun 04, 2026, 04:35 ET World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA
is a recombinant human anti-CLDN18.2 monoclonal antibody-drug conjugate (ADC) developed by Innovent Biologics. It specifically binds to the tumor cells expressing CLDN18.2, triggering CLDN18.2-dependent internalization of the ADC. Once inside the cell, the cytotoxic payload is released, resulting in DNA
More news about: Innovent Biologics
Jun 03, 2026, 16:05 ET ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
therapy.About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).ADC Therapeutics'
More news about: ADC Therapeutics SA
Jun 03, 2026, 03:00 ET Ingenix Raises €13m From Sofinnova Partners-Led Syndicate to Scale Modality Fusion, a Novel Architecture for Drug Development
compounds. We're thrilled to back a team that gets that."The Engine in Action: ADC Payload PrioritizationIn a recent engagement, Ingenix applied its Biological Reasoning Engine to a dual-payload ADC prioritization problem for an oncology biotech which had thousands of possible payload
More news about: Ingenix